Ziv&#45

2 trials

Sponsors

Ministry of public health, Invitation research fund Faculty of medicine, Khonkaen University

Conditions

Age related macular degeneration with serosanguinous maculopathy without prior treatment Choroidal neovascularization and its complication at macular area AMD CNV BCVAcentral retinal vein occlusion central retinal vein occlusion macular edema central subfield thickness more than 300 micron

Unknown Phase

A randomized, multi-centered study of ziv-aflibercept versus bevazicumab on visual outcomes in patients with wet Aged-related macular degeneration

RecruitingTCTR20180831001

Ministry of public healthAge related macular degeneration with serosanguinous maculopathy without prior treatment Choroidal neovascularization and its complication at macular area AMD CNV BCVA

Start: 2018-01-07Target: 450Updated: 2026-08-03

Ziv-aflibercept versus bevacizumab for treatment of CRVO with macular edema..

Active, not recruitingTCTR20191205008

Invitation research fund Faculty of medicine, Khonkaen Universitycentral retinal vein occlusion central retinal vein occlusion macular edema central subfield thickness more than 300 micron

Start: 2019-12-16Target: 42Updated: 2026-08-03

Ziv-aflibercept versus bevacizumab for treatment of CRVO with macular edema..

Active, not recruitingTCTR20191205008

Invitation research fund Faculty of medicine, Khonkaen Universitycentral retinal vein occlusion central retinal vein occlusion macular edema central subfield thickness more than 300 micron

Start: 2019-12-16Target: 42Updated: 2026-08-03

Related Papers

Intravitreal Ziv-Aflibercept versus Bevacizumab for Naïve Central Retinal Vein Occlusion with Macular Edema: An Interim Analysis of a Randomized Non-Inferiority Trial

Clinical ophthalmology2023-09-011 citations